Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease
Annals of the Rheumatic Diseases · 2026-01 · 85 (1) · 103-113
DOI: 10.1016/j.ard.2025.08.028 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Annals of the Rheumatic Diseases, 2026-01. Verfasst von Jon T Giles und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Kao Autoimmunity Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. Electronic address: jon.giles@cshs.org. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Atherosclerosis, Cardiovascular Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Pfizer.
Abstract (Originalsprache)
OBJECTIVES: This study aims to assess statin usage and its association with incident major adverse cardiovascular (CV) events (MACE) in patients with rheumatoid arthritis (RA) treated with tofacitinib vs tumour necrosis factor inhibitors (TNFi) in ORAL Surveillance. METHODS: Patients with RA aged ≥50 years and ≥1 additional CV risk factor received tofacitinib 5 mg (N = 1455) or 10 mg twice a day (N = 1456) or TNFi (N = 1451). Statin treatment was assessed at baseline and during the study. Hazard ratios (HR) were evaluated for MACE in participants with a history of atherosclerotic cardiovascular disease (ASCVD) and in categories of predicted CV risk. RESULTS: Among participants with a history of ASCVD or high CV risk, 53.0% and 26.9%, respectively, used a statin at baseline. Baseline statin use was similar in tofacitinib and TNFi-treated participants. In participants with or without statins, low-density lipoprotein and high-density lipoprotein increased from baseline and to a larger extent with tofacitinib than with TNFi. Occurrence of MACE in participants with a history of ASCVD and no use of statins at any time was higher with tofacitinib vs TNFi (HR 4.07 [95% CI 1.20-13.82]). In participants with a history of ASCVD and use of statins at baseline or at any time, there was no difference in incident MACE with tofacitinib vs TNFi (HR 1.17 [95% CI 0.46-3.00]). CONCLUSIONS: This post hoc analysis of ORAL Surveillance emphasises the gap in the CV preventive care of patients with RA. Among patients with a history of ASCVD, use of statins may mitigate the previously reported MACE risk observed to accompany tofacitinib use vs TNFi. This trial was registered with NCT number NCT02092467.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology and Kao Autoimmunity Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. Electronic address: jon.giles@cshs.org.
- Division of Rheumatology, Department of Medicine, University of California, Los Angeles, CA, USA.
- Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester…
- Université de Paris, Paris, France; Department of Rheumatology, Hôpital Cochin, Paris, France; Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne…
- Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Division of Rheumatology and Immunology, University of Nebraska Medical Center and VA Nebraska Western Iowa Health Care System, Omaha, NE, USA.
Förderung
- Pfizer
Zitieren
APA
Giles, J. T., Charles-Schoeman, C., Buch, M. H., Dougados, M., Szekanecz, Z., Mikuls, T. R., Ytterberg, S. R., Koch, G. G., Kwok, K., Cadatal, M. J., Menon, S., Chen, Y., Diehl, A. M., Rivas, J. L., Yndestad, A., & Bhatt, D. L. (2026). Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Annals of the Rheumatic Diseases, 85(1), 103-113. https://doi.org/10.1016/j.ard.2025.08.028
Vancouver
Giles JT, Charles-Schoeman C, Buch MH, Dougados M, Szekanecz Z, Mikuls TR, et al. Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Annals of the Rheumatic Diseases. 2026;85(1):103-113. doi:10.1016/j.ard.2025.08.028
BibTeX
@article{Giles2026,
author = {Giles, Jon T and Charles-Schoeman, Christina and Buch, Maya H and Dougados, Maxime and Szekanecz, Zoltán and Mikuls, Ted R and Ytterberg, Steven R and Koch, Gary G and Kwok, Kenneth and Cadatal, Mary Jane and Menon, Sujatha and Chen, Yan and Diehl, Annette M and Rivas, Jose L and Yndestad, Arne and Bhatt, Deepak L},
title = {Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {1},
pages = {103--113},
doi = {10.1016/j.ard.2025.08.028}
}
EUVIMED